Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493528 | 0.84 | HPGD (0.47) | KDM4EP2RX4DRD2ADRA1ADRD3 | |
| SCHEMBL6245432 | 0.83 | MEN1 (0.55) | KDM4ESMN1; SMN2P2RX4ALOX15MEN1 | |
| SCHEMBL4137357 | 0.83 | NAAA (0.58) | DRD2ADRA1ADRD3HTTALDH1A1 | |
| SCHEMBL20266341 | 0.81 | PKM (0.47) | KDM4ESMN1; SMN2DRD2ADRA1ADRD3 | |
| SCHEMBL7382368 | 0.81 | DRD2 (0.49) | DRD2ADRA1ADRD3ALDH1A1 | |
| SCHEMBL19333855 | 0.81 | DRD2 (0.46) | KDM4ESMN1; SMN2DRD2ADRA1ADRD3 | |
| SCHEMBL9521252 | 0.80 | ITGB3 (0.46) | KDM4ESMN1; SMN2DRD2ADRA1ADRD3 | |
| SCHEMBL10824954 | 0.80 | PKM (0.46) | KDM4ESMN1; SMN2DRD2ADRA1ADRD3 | |
| SCHEMBL4486369 | 0.80 | POLB (0.53) | KDM4ESMN1; SMN2KMT2AHTTALDH1A1 | |
| SCHEMBL16835726 | 0.79 | DRD2 (0.47) | KDM4ESMN1; SMN2DRD2ADRA1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | KDM4E 1695/4885SMN1; SMN2 3892/4885P2RX4 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.